VALUATION OF BIOTECHNOLOGY COMPANIES: REAL OPTIONS APPROACH UNDER UNCERTAINTY

Isidora Ljumovic, Janko Cvijanovic and Jelena Lazic

Economics of Agriculture, 2012, vol. 59, issue 01, 12

Abstract: Biotechnology is one of the most intensive industries in the past few decades. Essence of their operations leads to problem of determining the value of biotechnology companies, because in addition to their existing value, future product, market opportunities and intangible assets are difficult to value. Biotech companies don’t have a standard format, and simple techniques, such as financial statements analysis or discounted cash flows cannot be applied. Due to the complexity of their work and high levels of risk, alternative method such as real options is applied. The concept of financial options can be extended to the valuation of investment opportunities in commercial companies, especially in biotech. This paper explains how real options provide various perspectives on the project (investment) value in relation to situations in which the project is: delayed, expanded, abandoned, business is contracted, operations are switched, products with multiple applications are grown, and optimal date for the product launch is determined.

Keywords: Agribusiness; Risk and Uncertainty (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://ageconsearch.umn.edu/record/123958/files/4 ... janovic_%20Lazic.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ags:iepeoa:123958

DOI: 10.22004/ag.econ.123958

Access Statistics for this article

More articles in Economics of Agriculture from Institute of Agricultural Economics Contact information at EDIRC.
Bibliographic data for series maintained by AgEcon Search ().